Emergency-use spacers: a considerable option for asthmatic patients.
Omar Ahmed Sayed, Nabila Ibrahim Laz, Mohamed Ea Abdelrahim...
https://pubmed.ncbi.nlm.nih.gov/41483541/Actively Recruiting
Led by Beni-Suef University · Updated on 2025-02-10
120
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to compare emergency spacers to traditional spacers for delivering aerosolized drugs using pressurized metered-dose inhalers pMDIs in children and adults with asthma. It focuses on measuring the total drug dose emitted, the pharmacokinetics, lung and systemic bioavailability of aerosols, lung function after inhalation, and overall safety. The trial addresses issues with pMDI use and spacer materials, including electrostatic charge effects that impact drug delivery, especially important for young and elderly patients. Participants will inhale salbutamol through pMDI alone and with various traditional and emergency spacers, including devices made from everyday materials like plastic cups and paper sheets. The study includes in-vitro testing of emitted dose and particle size, in-vivo trials with 120 mild to moderate asthmatic patients assigned to 10 different spacer groups, and ex-vivo drug collection via filters at the mouth. Lung function tests, urine sampling, and heart rate monitoring will evaluate performance and safety. During the study, participants perform lung function tests before and 15 minutes after inhalation and provide urine samples 30 minutes and 24 hours post-dose to assess lung deposition and systemic absorption. Heart rate is monitored using a pulse oximeter. The study uses randomized assignment to various spacer types and measures outcomes such as total emitted dose, lung bioavailability, and heart rate over three to four months. Data analysis includes lung function parameters and safety monitoring, with participation lasting throughout the study period ending in February 2025.
CONDITIONS
Assessment of Emergency Spacers Versus Traditional Spacers for Delivery of Aerosolized Drugs
O
Omar Ahmed Sayed, Demonstrator
O
Omar Ahmed Sayed, Demonstrator
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Beni-Suef University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 to 4 months
Participants use a pressurized metered-dose inhaler (pMDI) alone or connected to various spacers to deliver aerosolized drugs and undergo lung function tests, urine sampling, and heart rate monitoring to evaluate efficacy and safety.
1 baseline visit and 1 follow-up visit within 3 to 4 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
10
Have more questions? Get in touch with our team for quick support
Omar Ahmed Sayed, Nabila Ibrahim Laz, Mohamed Ea Abdelrahim...
https://pubmed.ncbi.nlm.nih.gov/41483541/Beni-Suef University
Lead Sponsor